MRM Health Reports Safety and Positive Efficacy Data in Pouchitis in Phase 2a Clinical Study with MH002
Met primary endpoint of safety: MH002 was safe and well tolerated with no evidence of adverse reactions when administered for 8 weeks. Clinical remission rate of 46% at week 8, a mean decrease in the modified Pouchitis Disease Activity Index (mPDAI) symptom sc





